"Captive hospital pharmacies turn patients into price-takers." Examine the role of competition law and judicial oversight in correcting this.

Once a patient is admitted, they cannot shop around. The hospital picks the brand and its in-house pharmacy sells it. The Supreme Court recently flagged a cancer drug with a Price to Retailer (PTR) of ₹2,700 but an MRP of ₹27,000 [1]. Competition law and the courts have exposed this distortion, but neither can correct it alone.

Why patients become price-takers

• Lock-in: hospital protocols and fear of medical risk push admitted patients to the in-house pharmacy [3].
• Principal–agent failure: the hospital chooses the brand, so drug firms compete for hospitals by offering wide PTR–MRP gaps. They do not compete for patients through low prices.
• Regulatory blind spot: DPCO 2013 caps prices but not trade margins. Margin caps are allowed only for a limited period, and price-to-stockist data is not made public [5].

Role of competition law

• Strength: the CCI Director General's probe into Delhi hospitals recorded the admitted-patient "lock-in" [3].
• Limit: in May 2026 the CCI closed 12 such cases. It held that hospitals compete in a broad Delhi-NCR market that patients choose from before admission, so no abuse of dominance was proved [3].
• The Competition Act, 2002 therefore struggles to deal with aftermarket exploitation of individual patients.

Role of judicial oversight

• Strength: in Siddharth Dalmia v. Union of India (2025) the Court linked medical facilities to Article 21 and directed States to frame policy [2].
• In September 2026 it called ten-fold markups "broad daylight dacoity", suggested a uniform margin, and asked the Centre to examine hospitals forcing patients to buy in-house [1].
• Limit: courts defer to policymakers. They can push the executive to act but cannot fix prices themselves.

Way forward

• Make Trade Margin Rationalisation a permanent part of DPCO. The 2019 cap of 30% on 42 cancer drugs cut prices of 526 brands by about 50% [4][5].
• Publish price-to-stockist versus MRP data [5].
• Give patients a legal right to buy medicines outside the hospital.
• Bring more drugs under NLEM ceiling prices, which already save patients about ₹3,788 crore a year [6].

Competition law has diagnosed the lock-in and the courts have added constitutional urgency, but the cure has to be regulatory. A permanent margin cap, price transparency and patient choice, enforced by the States, would give real meaning to the Article 21 right to health and to SDG target 3.8 on affordable medicines.